Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
61 /100
HIGH RISK
Score updated Oct 13, 2026

APRE — Aprea Therapeutics, Inc. Dilution Risk Tracker

Track APRE dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track APRE — Get alerts when the score changes →

As of October 13, 2026, Aprea Therapeutics, Inc. (APRE) has a DilutionWatch DilutionScore of 61/100, rated HIGH dilution risk. Aprea Therapeutics, Inc. has a market capitalization of $7.47M, 12.59M shares outstanding, 10 institutional holders tracked. Stored dilution-related fields include 89.64M outstanding warrants.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
80
💰 Cash Runway
0
📊 Float Risk
45
⚠️ Warrant Exposure
90
🔄 Convertible Debt
40

Dilution Forecast

⛈️
Warning
High probability of dilution event
model est. 48%
📜 Warrant Exercise model 60%
• Massive warrant overhang: 712% of shares outstanding
• Warrant risk score very high (90/100)
🔄 Reverse Split model est. 55%
• 50-day avg $0.84 below $1 exchange minimum
📉 Score Deterioration model 10%
• Score in HIGH risk zone (61/100)
🔔 Track APRE — Get forecast alerts →

Market Data

Market Cap$7.47M
Shares Outstanding12.59M
Float8.57M
Cash$41.23M
DebtN/A
Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

FieldCurrent ValueBasis
DilutionScore61/100DilutionWatch score record
Shares Outstanding12.59MVerified float table or market cache
Public Float8.57MVerified float table or market cache
Market Cap$7.47MMarket data cache
Cash Runway37.2 monthsDilutionWatch score inputs
Shelf CapacityNone in current score inputsSEC-derived dilution fields
ATM CapacityNone in current score inputsSEC-derived dilution fields
Outstanding Warrants89.64MSEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 7.

Recent SEC source mix: 4 2, 424B3 1, EFFECT 1, S-3 1, XBRL 2.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

Institutional Holdings

10 institutional holders · 1.58M shares
#1 AIGH Capital Management LLC 370.5K shares
#2 Murchinson Ltd. 340.1K shares
#3 Sphera Funds Management Ltd. 270.0K shares
+ 7 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest508.8K
Days to Cover2.5
% of Float5.9%
FINRA data as of Sep 30, 2026

Recent SEC Activity

xbrl XBRL WARRANT 2026-08-12
xbrl XBRL CONVERTIBLE 2026-03-16
EFFECT EFFECT 2026-04-29
424B3 ATM 2026-04-29
S-3 SHELF 2026-04-22
Full SEC filing analysis available with free account →

Recent News

No recent news available for this ticker.

Factual APRE Dilution Snapshot

Aprea Therapeutics, Inc. (APRE) has a DilutionScore of 61/100, rated High dilution risk. Score date: October 13, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

DilutionScore History — Last 90 Days

APRE's DilutionScore is currently 61/100 (High risk), with 3 score changes tracked over 89 days. The score improved from 51/100 (High risk).

Period Score Risk Level Duration
Sep 28 – Oct 13, 202661/100HIGH16 days
Aug 22 – Sep 27, 202651/100HIGH37 days
Aug 14 – Aug 21, 202661/100HIGH7 days
Jul 16 – Aug 13, 202651/100HIGH29 days

Score recalculated daily from SEC filings and market data. Sign up free for real-time score change alerts.

Share Dilution History

APRE shares outstanding have increased 8.1% from 11.45M (Mar 2026) to 12.38M (May 2026). Each increase represents potential dilution to existing shareholders.

Date Shares Outstanding Public Float Change
May 15, 202612.38M8.57M▲ 8.12%
May 09, 202612.38M7.93M▲ 2.10%
May 01, 202611.98M7.76M▼ 11.57%
Apr 07, 202611.45M8.78M▼ 12.65%
Mar 30, 202611.45M10.05M▼ 0.01%
Mar 25, 202611.45M10.05M▲ 5.86%
Mar 23, 202611.45M9.50M▲ 81.48%
Mar 22, 202611.45M5.23M▲ 11.01%

Share counts sourced from verified regulatory filings. Increases indicate dilution events.

Track APRE Dilution Risk in Real-Time
DilutionWatch monitors SEC filings 24/7 and alerts you the moment APRE files a shelf registration, ATM offering, warrant notice, or convertible note. Free tier available — no credit card required.
Start Tracking APRE — Free
Email alert within minutes of any SEC filing Daily DilutionScore™ recalculation Score history & trend tracking Tracks 8,000+ tickers simultaneously

Related Stocks — HIGH Risk

Other HIGH dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,490+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for APRE
APRE FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.